Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Dec 07, 2022 11:45am
RE:RE:RE:Cancellation
Yup - they've never issued at lower valuations - only higher valuations.
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 06, 2022 2:57pm
RE:RE:RE:Cancellation
Stiffing investors who buy the PP is never a good idea. They have long memories. Further it does not help making deal and MA with other companies either. But some lo..sers in this forum who lost
...more
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
posted Nov 14, 2024 9:00am by
NurExone Biologic Inc.
-
|
“We are honored by the EMA’s recognition of ExoPTEN through the Orphan Medicinal Product Designation, which significantly advances our ability to enter the European market and offers hope to those impacted by acute spinal cord injuries,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This designation, together with the ...read more
(6)
•••
EbbFlow88
X
View Profile
View Bullboard History
Comment by
EbbFlow88
on Dec 06, 2022 10:19am
RE:RE:RE:Cancellation
Especially when it comes from cash from operations. For those interested, Mohnish Pabrai did a very interesting analysis of companies that perform share buybacks over long periods of time and what
...more
(1)
•••
Marclecon2
X
View Profile
View Bullboard History
Comment by
Marclecon2
on Dec 06, 2022 9:48am
RE:RE:Cancellation
I don't see any problem about that: sell at 10 and buyback at 5
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 06, 2022 9:43am
RE:Cancellation
They continue to over pay. What will they do when they run out of cash? Ho ......I forgot they will do a new issue PP a $5 and later buy back shares at $3. The last time they did a PP at $10 and
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Dec 05, 2022 8:46pm
Cancellation
Cancellation of ~450,000 shares. EOM
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Dec 01, 2022 4:15pm
Correct !
Superimpose 8 years of GUD on the first of 19 for PLB - you will see exactly what sideways movement means. It's a very long investment cycle - I have been clear on that since Day 1. I floated
...more
(14)
•••
Lookingforclues
X
View Profile
View Bullboard History
Post by
Lookingforclues
on Dec 01, 2022 1:49pm
Mugsy on Paladin.
Just looked at CEO! Paladin is their Saviour again, again etal.
(14)
•••
Lookingforclues
X
View Profile
View Bullboard History
Post by
Lookingforclues
on Dec 01, 2022 1:47pm
Mugsy…said Sideways.d
Doesn't seem that sideways is pointing down! Tough to fathom! Huh.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 01, 2022 7:30am
New Press Release - Knight Announces Relaunch of AKYNZEO® in Canada
MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO® (netupitant/palonosetron capsules) in Canada...
read article.
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 30, 2022 9:44am
Horizon - Rare diseases and therapies being discussed,CNBC
& focus on Horizon therapeutics. horizon in prelim sales talks with Amgen, sanitize, j&j. Saying biotech and pharma are in a diff space and not aligned with market moves .. long
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 28, 2022 5:39pm
RE:Decreasing volume/turnover?
Ya - Armoyan is an early adoptor. Others will eventually follow. I think that's still one or two big drug mores away - then you have to see the revenue effects - before others say ... water is
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 28, 2022 5:30pm
RE:Biogen’s Alzheimer’s woes
Ya - seems that brain swelling is also an issue with this drug. Exactly why I prescribe to a future of reducing inflammation and reduced neuroinflammation via H2S gaseous mediatioin. A healthier
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 28, 2022 3:05pm
Biogen’s Alzheimer’s woes
Vs our established therepy Biogen — Biogen’s stock fell nearly 4% after a Science.org report that a woman participating in an experimental Alzheimer’s treatment trial, sponsored by Biogen and
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Explained: The Psychology of Options Trading with Practical Tips
Meet the Top 5 Best Online Brokerages in Canada
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Major Funding Secured! Company Closes First Round of Private Placement
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Gold, growth and sustainability in focus for this resource company
Star Diamond Corporation Announces Third Quarter 2024 Results
This $10M Deal Could Reshape the Future of Global Creator Platforms
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits